KATHLEEN KISSINGER: Open Payments
NPI 1194225524 · AMSTERDAM, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,513 in 114 payments from 19 companies in 2025. Trend: 2023 $3,248 · 2024 $1,893 · 2025 $2,513
Food & beverage: $2,513
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $690 |
| UCB, Inc. | 17 | $389 |
| Janssen Biotech, Inc. | 14 | $323 |
| Amgen Inc. | 12 | $203 |
| PFIZER INC. | 8 | $186 |
| Lilly USA, LLC | 7 | $150 |
| GlaxoSmithKline, LLC. | 5 | $122 |
| Novartis Pharmaceuticals Corporation | 4 | $96 |
| Genentech USA, Inc. | 5 | $81 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $43 |
Products named: RINVOQ, Bimzelx, TREMFYA, SKYRIZI, XELJANZ, TALTZ, BENLYSTA, ENBREL.
Industry payments across NY — which companies pay providers there.
